` 6978 (Immunotech Biopharm Ltd) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

6978
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, Immunotech Biopharm Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +30% compared to the Hang Seng (Hong Kong)'s +29% growth.

Stocks Performance
6978 vs Hang Seng (Hong Kong)

Loading
6978
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
6978 vs Hang Seng (Hong Kong)

Performance Gap Between 6978 and HSI
HIDDEN
Show

Performance By Year
6978 vs Hang Seng (Hong Kong)

Loading
6978
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Immunotech Biopharm Ltd vs Peers

Hang Seng (Hong Kong)
6978
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Immunotech Biopharm Ltd
Glance View

Market Cap
1.6B HKD
Industry
Biotechnology

Immunotech Biopharm Ltd. operates as an investment holding company, which through its subsidiaries engages in research and development, manufacturing and commercialization of immune cell products for treatments of cancers in the PRC. The company is headquartered in Beijing, Beijing and currently employs 515 full-time employees. The company went IPO on 2020-07-10. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. The company also provides cell cryopreservation services. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
Not Available
Back to Top